Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
Commercial & Investment Banking, Picture Gallery Monday, February 13th, 2017
LOS ANGELES, CA — (Marketwired) — 02/13/17 — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with Dr. B Brett Finlay from the Michael Smith Laboratories at the University of British Columbia ("UBC") to study the role of the microbiome and RP-G28 in environmental ente
